# 2025-04026: FDA Gives Extra Time for Drug Study Feedback: Yawn.

2025-04026, E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-13, effective 2025-03-13; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04026
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04026
- Title: E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 11985
- Published: 2025-03-13
- Effective: 2025-03-13
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

FDA Gives Extra Time for Drug Study Feedback: Yawn.

## Summary

The FDA is giving everyone more time to share their thoughts on the draft rules for good clinical practice in drug studies, called E6(R3) Annex 2. This affects drug companies and researchers who want to make sure their studies meet the latest safety and quality standards. Comments are now open until March 31, 2025, so get your feedback in before the final rules are set—no extra costs, just your voice!

## Abstract

The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the draft guidance for industry entitled "E6(R3) Good Clinical Practice: Annex 2," announced in the Federal Register of December 30, 2024. The Agency is taking this action to allow interested persons additional time to submit comments.

## Effects PRIA read

- Comment Period Extended to March 31, 2025: benefit, low. The FDA reopened the public comment period for the draft guidance "E6(R3) Good Clinical Practice: Annex 2" so interested persons may submit comments through March 31, 2025. The original deadline had been February 28, 2025; submit comments to Docket No. FDA-2024-D-5601 via https://www.regulations.go…
- Guidance Targets Decentralized Trials and Real-World Data: benefit, low. The draft guidance provides Good Clinical Practice considerations specifically for trial design and conduct that include decentralized and pragmatic elements and for trials that utilize real-world data. Annex 2 is intended to be read and implemented with the E6(R3) Principles and Annex 1.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-04026 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/13/2025-04026/e6r3-good-clinical-practice-annex-2-international-council-for-harmonisation-draft-guidance-for)
- [2025-04026 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-13/pdf/2025-04026.pdf)

## Related
- [Previous: 2025-04024, Taking and Importing Marine Mammals; Taking Marine Mammals Incidental to Geophy…](https://policyrisk.com/federal-register/2025-04024)
- [Next: 2025-04027, Atlantic Highly Migratory Species; Schedules for Atlantic Shark Identification…](https://policyrisk.com/federal-register/2025-04027)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04026 (as of 2026-09-30).
